Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 2/20 | 0.40 |
| ▸ | CCKAR | P32238 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830151 | 0.90 | ALB (0.42) | NR1H4ALBCCKARNSD2RXFP1 | |
| SCHEMBL6833910 | 0.88 | KDM4E (0.45) | NR1H4ALBNSD2RXFP1POLB | |
| SCHEMBL6830640 | 0.88 | NR1H4 (0.40) | NR1H4ALBCCKARRXFP1 | |
| SCHEMBL6833897 | 0.88 | ALB (0.42) | NR1H4ALBNSD2RXFP1NHERF1 | |
| SCHEMBL6835677 | 0.87 | CCKAR (0.41) | NR1H4ALBCCKARNSD2NHERF1 | |
| SCHEMBL6835807 | 0.87 | ALB (0.41) | NR1H4ALBNSD2RXFP1NHERF1 | |
| SCHEMBL6830655 | 0.87 | ALB (0.43) | NR1H4ALBNSD2RXFP1POLB | |
| SCHEMBL6833683 | 0.87 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL6833137 | 0.87 | MAP3K5 (0.44) | NR1H4ALBCCKARNSD2RXFP1 | |
| SCHEMBL6835693 | 0.86 | POLB (0.47) | ALBRXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | NR1H4 1201/4885ALB 1417/4885CCKAR 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.